VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a company specializing in commercial-stage regenerative medicine and pioneering devices for wound care management and skin restoration, today announced it has entered into an exclusive distribution agreement with Revolution Surgical Pty Ltd. This agreement marks an important milestone in our expansion into the Australian and New Zealand markets. Under the terms of the agreement, Revolution Surgical will serve as the exclusive distributor of the RECELL® product platform, including RECELL GO® (pending regulatory approval), in Australia and New Zealand. This partnership aims to enhance the avail

VALENCIA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O'Toole, Chief Financial Officer, on November 12, 2024, at 2:00 p.m. Pacific Standard Time (November 13, 2024, at 9:00 a.m. Australian Eastern Daylight Time). The webinar presentation will cover financial and business results from our recent third-quarter 2024 earnings webcast and will conclude with a Q&A se

VALENCIA, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the third quarter ended September 30, 2024. Financial Results and Recent Business Updates Commercial revenue of $19.5 million, an increase of approximately 44% compared to the same period in 2023Gross profit margin of 83.7%On July 31, 2024, entered into a multi-year development and distribution agreement with Regenity Biosciences that provides AVITA Medical with the exclusive rights to market, sell, and distribute Cohealyx™, a

VALENCIA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on Thursday, November 7, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 8, 2024, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the A

VALENCIA, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O'Toole, Chief Financial Officer, will present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 9:10 a.m. Eastern Time. A live webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at https://ir.avitamedical.com. A replay of the webcast will be available following the conclusion of the event. About AVITA Medical, Inc.AVITA Medical® is a comm

VALENCIA, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that management will participate in Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference in New York on September 12, 2024. Jim Corbett, Chief Executive Officer, will host one-on-one meetings with institutional investors throughout the day. For more information or to schedule a meeting, please contact your Lake Street representative. About AVITA Medical, Inc.AVITA Medical® is a commercial-stage regenerative medicine compan

VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O'Toole, Chief Financial Officer, on August 13, 2024, at 4:00 p.m. Pacific Daylight Time (August 14, 2024, at 9:00 a.m. Australian Eastern Standard Time). The webinar presentation will cover financial and business results from our recent second-quarter 2024 earnings webcast and will conclude with a Q&A sessio

VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the second quarter ended June 30, 2024. Financial Results and Recent Business Updates Commercial revenue of $15.1 million, an increase of approximately 29% compared to the same period in 2023Gross profit margin of 86.2%RECELL GO™ premarket approval (PMA) supplement approved by the FDA on May 29, 2024; first case completed on May 31, 2024Submitted PMA supplement for RECELL GO mini™, designed to address smaller wounds, on June

VALENCIA, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, is pleased to announce that industry leader Robin VanDenburgh has joined as Senior Vice President of U.S. Commercial Sales, effective August 6, 2024. VanDenburgh, who most recently served as Vice President of Key Accounts at Smith & Nephew (NYSE:SNN), will spearhead AVITA Medical's efforts to expand its market presence and drive sales growth in the U.S. "Robin brings a wealth of experience in leading and developing high-performing sales teams," said Jim Corbett,

VALENCIA, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced it has entered into an exclusive multi-year development and distribution agreement with Regenity Biosciences ("Regenity"), a leading regenerative medical product developer and manufacturer of bioresorbable technologies. Through this agreement, following 510(k) by the FDA, AVITA Medical will hold the exclusive marketing, sales and distribution rights to a unique collagen-based dermal matrix, which will be manufactured by Regenity. "This strategic c

10-Q - AVITA Medical, Inc. (0001762303) (Filer)

8-K - AVITA Medical, Inc. (0001762303) (Filer)

S-8 - AVITA Medical, Inc. (0001762303) (Filer)

10-Q - AVITA Medical, Inc. (0001762303) (Filer)

8-K - AVITA Medical, Inc. (0001762303) (Filer)

8-K - AVITA Medical, Inc. (0001762303) (Filer)

8-K - AVITA Medical, Inc. (0001762303) (Filer)

8-K - AVITA Medical, Inc. (0001762303) (Filer)

8-K - AVITA Medical, Inc. (0001762303) (Filer)

10-Q - AVITA Medical, Inc. (0001762303) (Filer)

4 - AVITA Medical, Inc. (0001762303) (Issuer)

4 - AVITA Medical, Inc. (0001762303) (Issuer)

4 - AVITA Medical, Inc. (0001762303) (Issuer)

4 - AVITA Medical, Inc. (0001762303) (Issuer)

4 - AVITA Medical, Inc. (0001762303) (Issuer)

4 - AVITA Medical, Inc. (0001762303) (Issuer)

4 - AVITA Medical, Inc. (0001762303) (Issuer)

AVITA Medical (NASDAQ:RCEL) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $19.0, a high estimate of $25.00, and a low estimate of $9.00. A negative shift in sentiment is evident as analyst

Piper Sandler analyst Matt O'Brien downgrades AVITA Medical (NASDAQ:RCEL) from Overweight to Neutral and lowers the price target from $21 to $9.

Cantor Fitzgerald analyst Ross Osborn maintains AVITA Medical (NASDAQ:RCEL) with a Overweight and lowers the price target from $22 to $21.

Financial GuidanceCommercial revenue for the second quarter 2024 is expected to be in the range of $14.3 to $15.3 millionCommercial revenue for the full-year 2024 is expected to be in the lower end of our previously provided guidance range of $78.5 to $84.5 million, reflecting growth of approximately 57% at the lower end of the range over the full-year 2023Expect to achieve previously given guidance of cashflow break even and GAAP profitability no later than the third quarter of 2025"We acknowledge the significant cash utilization this quarter, however we remain confident in our financial stability and our ability to reach cashflow break even as guided," said David O'Toole, Chief Financial O

AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.45) by 62.22 percent. This is a 97.3 percent decrease over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $11.10 million which beat the analyst consensus estimate of $11.05 million by 0.49 percent. This is a 5.25 percent increase over sales of $10.55 million the same period last year.

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83. The S&P 500 also rose, gaining, 0.83% to 5,203.26. Check This Out: How To Earn $500 A Month From Citigroup Stock Ahead Of Q1 Earnings Report   Leading and Lagging Sectors   Information technology shares rose by 2.2% on Thursday. In trading on Thursday, energy shares fell by 0.3%.   Top Headline   Constellation Brands Inc (NYSE:STZ) reported better-than-expected fourth-quarter earnings. Constellation Brands reported fourth-quarter FY24 sales growth of 7.1% year-on-year to $2.14 billi

Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents. Fastenal shares dipped 6.7% to $69.73 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Rallybio Corporation (NASDAQ:RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rent the Runway, Inc. (NA

Gainers Rallybio (NASDAQ:RLYB) shares moved upwards by 70.5% to $2.78 during Thursday's regular session. The company's market cap stands at $105.1 million. Eliem Therapeutics (NASDAQ:ELYM) shares rose 57.3% to $4.2. The market value of their outstanding shares is at $116.4 million. Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 40.58% to $7.17. The market value of their outstanding shares is at $210.4 million. Alpine Immune Sciences (NASDAQ:ALPN) stock moved upwards by 36.84% to $64.37. The company's market cap stands at $4.2 billion. Akanda (NASDAQ:AKAN) shares moved upwards by 29.51% to $0.15. The company's market cap stands at $1.8 million. Nektar Therapeutics (NASDAQ:NKT

BTIG Research downgraded Avita Medical from Buy to Neutral

Cantor Fitzgerald initiated coverage of Avita Medical with a rating of Overweight and set a new price target of $23.00

Piper Sandler initiated coverage of AVITA Medical with a rating of Overweight and set a new price target of $27.00

Piper Sandler initiated coverage of AVITA Medical with a rating of Overweight and set a new price target of $27.00

VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023. O'Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public

VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023. Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and financial management spans across early stage, high growth, and mature companies. He

VALENCIA, Calif. and MELBOURNE, Australia, March 16, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Cary Vance to its Board of Directors, effective April 1, 2023. Mr. Vance has over 25 years of extensive leadership experience with commercial and operational expertise in the healthcare industry. He is currently the President and Chief Executive Officer of Titan Medical, a position he has held since July 2022. Prior to this appointment, he served as an independent director f

VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the results of its 2022 Annual Meeting of Stockholders, which was held virtually on December 12, 2022 (United States) (being December 13, 2022 in Australia). Election of Directors: All five directors named in the Company's proxy statement dated October 19, 2022 (Proxy Statement) were elected or re-elected, as applicable, to serve on the Company's Board of Directors: Louis Panaccio, Ch

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of James Corbett as Chief Executive Officer, effective immediately. Mr. Corbett, who has served as a non-executive member of the Board of Directors, will continue as an executive member of the Board of Directors of AVITA Medical, Inc. Mr. Corbett, has nearly 40 years of experience in the Life Sciences field, having served as CEO of multiple publicly traded companies, including:

VALENCIA, Calif. and MELBOURNE, Australia, April 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that Louis Drapeau has resigned, effective April 29, 2022, from the Company's Board of Directors. Mr. Drapeau's resignation is not because of a disagreement with the Company on any matter relating to the Company's operations, policies or practices. Rather, his resignation is due to personal reasons. Mr. Drapeau has been a non-executive Director of AVITA Medical since

VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an

VALENCIA, Calif. and MELBOURNE, Australia, March 22, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of Michael Holder as Chief Financial Officer effective March 22, 2021. Mr. Holder will assume responsibility for overseeing the global finance, accounting, M&A, and investor relations functions and will be based in AVITA’s Valencia office in California. “Michael’s extensive background in finance, M&A, business development, strategy, and operati

VALENCIA, Calif, and MELBOURNE, Australia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020. “Kathy’s extensive healthcare experience and industry insight are a welcome addition to AVITA’s leadership team,” said Dr. Mike Perry, AVITA Therapeutics’ Chief Executive Officer. “In particular her broad operational experience within Regenerative Medicine will be critically important as we s